

Abeome Announces a Collaboration with Medicago to Develop Neutralizing Monoclonal Antibodies to the H5N1 and H1N1 Influenza VLPs

Athens, GA, March 12, 2010, Abeome Corporation, a Georgia-based biotech company, today announced a collaboration with Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), to develop neutralizing monoclonal antibodies to Medicago's H5N1 and H1N1 VLPs using its patented DiSH (Direct Selection of Hybridoma) technology.

"Availability of a neutralizing antibody treatment for patients suffering from severe influenza disease would greatly improve upon the current antiviral treatments which typically provide benefit only when administered shortly after the onset of infection," states Mike Wanner, President and CEO of Abeome. "Medicago's influenza VLP vaccines which contain the most abundant surface protein of the influenza virus will aid us in developing a significant library of antibodies to screen for high affinity and cross-reactivity with a number of influenza-types."

"Collaborating with Abeome, a biotech company focused on the commercialization of its patented mAb-discovery platform, will potentially enhance access to unique, highly-specific mAbs to the influenza viruses." said Andy Sheldon, President and CEO of Medicago.

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

About Abeome

Abeome Corporation is a biotechnology company dedicated to leveraging its proprietary hybridoma technology to accelerate and improve the development of monoclonal antibodies for life sciences. Abeome owns an exclusive license for the technology from the University of Georgia Research Foundation and is presently in pre-clinical studies on an ovarian cancer therapeutic. Abeome's long term focus is on developing cancer therapeutics and diagnostics.

For more information on Abeome, visit www.abeomecorp.com.